Barsky S, Mcphail K, Wang J, Hoffman R, Ye Y
Int J Mol Sci. 2025; 26(4).
PMID: 40004162
PMC: 11855042.
DOI: 10.3390/ijms26041699.
Lopez-Collazo E, Hurtado-Navarro L
Front Immunol. 2025; 16:1524781.
PMID: 39967663
PMC: 11832717.
DOI: 10.3389/fimmu.2025.1524781.
Hwang S, Park J, Koo S, Lee S, Jo Y, Ryu D
Nat Commun. 2025; 16(1):1256.
PMID: 39893188
PMC: 11787384.
DOI: 10.1038/s41467-025-56440-6.
Wang Y, Li T, Wang F, Yao X, Bai Q, Su H
Int J Biol Sci. 2025; 21(2):632-657.
PMID: 39781471
PMC: 11705649.
DOI: 10.7150/ijbs.104404.
Nguyen D, Kang M, Oh S, Park H, Kim S, Yu J
Anim Cells Syst (Seoul). 2025; 29(1):24-34.
PMID: 39777026
PMC: 11703389.
DOI: 10.1080/19768354.2024.2442401.
Oxidized mRNA Lipid Nanoparticles for Chimeric Antigen Receptor Monocyte Engineering.
Mukalel A, Hamilton A, Billingsley M, Li J, Thatte A, Han X
Adv Funct Mater. 2024; 34(27).
PMID: 39628840
PMC: 11611297.
DOI: 10.1002/adfm.202312038.
A multiscale model of immune surveillance in micrometastases gives insights on cancer patient digital twins.
L Rocha H, Aguilar B, Getz M, Shmulevich I, Macklin P
NPJ Syst Biol Appl. 2024; 10(1):144.
PMID: 39627216
PMC: 11614875.
DOI: 10.1038/s41540-024-00472-z.
Immunological Pre-Metastatic Niche in Dogs With Naturally Occurring Osteosarcoma.
Kerboeuf M, Anfinsen K, Koppang E, Lingaas F, Argyle D, Teige J
Vet Comp Oncol. 2024; 23(1):62-72.
PMID: 39526499
PMC: 11830463.
DOI: 10.1111/vco.13026.
Targeting of TAMs: can we be more clever than cancer cells?.
Kzhyshkowska J, Shen J, Larionova I
Cell Mol Immunol. 2024; 21(12):1376-1409.
PMID: 39516356
PMC: 11607358.
DOI: 10.1038/s41423-024-01232-z.
Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches.
Naji O, Ghouzlani A, Rafii S, Sadiqi R, Kone A, Harmak Z
Front Immunol. 2024; 15:1399754.
PMID: 39507526
PMC: 11538072.
DOI: 10.3389/fimmu.2024.1399754.
Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures.
Kabiljo J, Theophil A, Homola J, Renner A, Sturzenbecher N, Ammon D
J Immunother Cancer. 2024; 12(11).
PMID: 39500527
PMC: 11535717.
DOI: 10.1136/jitc-2024-009494.
Type 2-like polarization and elevated CXCL4 secretion of monocyte derived macrophages upon internalization of plasma-derived exosomes from head and neck cancer patients.
Theodoraki M, Huber D, Hofmann L, Werner L, Idel C, Fleckner J
BMC Cancer. 2024; 24(1):1173.
PMID: 39304856
PMC: 11414076.
DOI: 10.1186/s12885-024-12948-6.
Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma.
Liu H, Lv Z, Zhang G, Yan Z, Bai S, Dong D
J Exp Clin Cancer Res. 2024; 43(1):242.
PMID: 39169402
PMC: 11340075.
DOI: 10.1186/s13046-024-03164-y.
The Role of Adipocytes Recruited as Part of Tumor Microenvironment in Promoting Colorectal Cancer Metastases.
Ma Y, Nenkov M, Chen Y, Gassler N
Int J Mol Sci. 2024; 25(15).
PMID: 39125923
PMC: 11313311.
DOI: 10.3390/ijms25158352.
FeO Nanoparticles That Modulate the Polarisation of Tumor-Associated Macrophages Synergize with Photothermal Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) to Enhance Anti-Tumor Therapy.
Sun H, Wang X, Guo Z, Hu Z, Yin Y, Duan S
Int J Nanomedicine. 2024; 19:7185-7200.
PMID: 39050876
PMC: 11268759.
DOI: 10.2147/IJN.S459400.
A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma.
Tang X, Shimada H, Ikegaki N
Curr Oncol. 2024; 31(6):3212-3226.
PMID: 38920727
PMC: 11202629.
DOI: 10.3390/curroncol31060243.
Failed Induction of the T1 System in T2 Dominant Patients: The Cancer-Permissive Immune Macroenvironment.
Yanuck S
Integr Med (Encinitas). 2024; 23(2):24-35.
PMID: 38911450
PMC: 11193407.
Harnessing the innate immune system by revolutionizing macrophage-mediated cancer immunotherapy.
Reghu G, Vemula P, Bhat S, Narayanan S
J Biosci. 2024; 49.
PMID: 38864238
PMC: 11286319.
Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review).
Su P, Li O, Ke K, Jiang Z, Wu J, Wang Y
Int J Oncol. 2024; 64(6).
PMID: 38695252
PMC: 11087038.
DOI: 10.3892/ijo.2024.5648.
Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells.
Renner A, Stahringer A, Ruppel K, Fricke S, Koehl U, Schmiedel D
Gene Ther. 2024; 31(7-8):378-390.
PMID: 38684788
PMC: 11257948.
DOI: 10.1038/s41434-024-00454-0.